Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer.

Morgan RD, Stamatopoulou S, Mescallado N, Saunders G, Welch R, Mitchell C, Hasan J, Clamp AR, Jayson GC.

ESMO Open. 2019 Mar 21;4(2):e000463. doi: 10.1136/esmoopen-2018-000463. eCollection 2019.

2.

Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases.

Morgan RD, Burghel GJ, Flaum N, Bulman M, Clamp AR, Hasan J, Mitchell CL, Schlecht H, Woodward ER, Lallo FI, Crosbie EJ, Edmondson RJ, Wallace AJ, Jayson GC, Evans DGR.

J Med Genet. 2019 May;56(5):301-307. doi: 10.1136/jmedgenet-2018-105792. Epub 2019 Jan 25.

PMID:
30683677
3.

Dose-dense cisplatin with gemcitabine for relapsed platinum-resistant ovarian cancer.

Morgan RD, Clamp AR, Zhou C, Saunders G, Mescallado N, Welch R, Mitchell C, Hasan J, Jayson GC.

Int J Gynecol Cancer. 2019 Jan 23. pii: ijgc-2018-000067. doi: 10.1136/ijgc-2018-000067. [Epub ahead of print]

PMID:
30674568
4.

Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer.

Jayson GC, Zhou C, Backen A, Horsley L, Marti-Marti K, Shaw D, Mescallado N, Clamp A, Saunders MP, Valle JW, Mullamitha S, Braun M, Hasan J, McEntee D, Simpson K, Little RA, Watson Y, Cheung S, Roberts C, Ashcroft L, Manoharan P, Scherer SJ, Del Puerto O, Jackson A, O'Connor JPB, Parker GJM, Dive C.

Nat Commun. 2018 Nov 7;9(1):4672. doi: 10.1038/s41467-018-07174-1.

5.

An Outpatient, Dose-Intense, Intravenous Cisplatin and Oral Etoposide Regimen for the Treatment of Advanced, Platinum-Resistant Ovarian Cancer.

Morgan RD, Clamp AR, Hasan J, Mitchell C, Saunders G, Mescallado N, Welch R, Jayson GC.

Int J Gynecol Cancer. 2018 Mar;28(3):448-452. doi: 10.1097/IGC.0000000000001194.

PMID:
29466253
6.

Characterisation and risk assessment of venous thromboembolism in gastrointestinal cancers.

Metcalf RL, Al-Hadithi E, Hopley N, Henry T, Hodgson C, McGurk A, Mansoor W, Hasan J.

World J Gastrointest Oncol. 2017 Sep 15;9(9):363-371. doi: 10.4251/wjgo.v9.i9.363.

7.

Malignant bowel obstruction in advanced ovarian cancer.

Dean E, Khoja L, Clamp A, Jayson GC, Goonetilleke D, Conway AM, Hasan J.

Future Oncol. 2017 Mar;13(6):513-521. doi: 10.2217/fon-2016-0431. Epub 2017 Jan 18.

PMID:
28095701
8.

Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer.

Krebs MG, Renehan AG, Backen A, Gollins S, Chau I, Hasan J, Valle JW, Morris K, Beech J, Ashcroft L, Saunders MP, Dive C.

Clin Colorectal Cancer. 2015 Jun;14(2):115-22.e1-2. doi: 10.1016/j.clcc.2014.12.006. Epub 2014 Dec 31.

PMID:
25680623
9.

Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer.

Khoja L, Kumaran G, Zee YK, Murukesh N, Swindell R, Saunders MP, Clamp AR, Valle JW, Wilson G, Jayson GC, Hasan J.

J Clin Gastroenterol. 2014 May-Jun;48(5):430-4. doi: 10.1097/MCG.0b013e3182a8804c.

PMID:
24153157
10.

A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours.

Horsley L, Cummings J, Middleton M, Ward T, Backen A, Clamp A, Dawson M, Farmer H, Fisher N, Halbert G, Halford S, Harris A, Hasan J, Hogg P, Kumaran G, Little R, Parker GJ, Potter P, Saunders M, Roberts C, Shaw D, Smith N, Smythe J, Taylor A, Turner H, Watson Y, Dive C, Jayson GC; Cancer Research UK Drug Development Office Phase I clinical trial.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1343-52. doi: 10.1007/s00280-013-2320-9. Epub 2013 Oct 20.

PMID:
24141375
11.

A phase 3 trial of bevacizumab in ovarian cancer.

Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators.

N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799. Erratum in: N Engl J Med. 2012 Jan 19;366(3):284.

12.

Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.

Griffiths RW, Zee YK, Evans S, Mitchell CL, Kumaran GC, Welch RS, Jayson GC, Clamp AR, Hasan J.

Int J Gynecol Cancer. 2011 Jan;21(1):58-65. doi: 10.1097/IGC.0b013e3182049273.

PMID:
21178570
13.

Targeted therapies in epithelial ovarian cancer.

Dean E, El-Helw L, Hasan J.

Cancers (Basel). 2010 Feb 23;2(1):88-113. doi: 10.3390/cancers2010088.

14.

Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging.

O'Connor JP, Carano RA, Clamp AR, Ross J, Ho CC, Jackson A, Parker GJ, Rose CJ, Peale FV, Friesenhahn M, Mitchell CL, Watson Y, Roberts C, Hope L, Cheung S, Reslan HB, Go MA, Pacheco GJ, Wu X, Cao TC, Ross S, Buonaccorsi GA, Davies K, Hasan J, Thornton P, del Puerto O, Ferrara N, van Bruggen N, Jayson GC.

Clin Cancer Res. 2009 Nov 1;15(21):6674-82. doi: 10.1158/1078-0432.CCR-09-0731. Epub 2009 Oct 27.

15.

Heparin octasaccharides inhibit angiogenesis in vivo.

Hasan J, Shnyder SD, Clamp AR, McGown AT, Bicknell R, Presta M, Bibby M, Double J, Craig S, Leeming D, Stevenson K, Gallagher JT, Jayson GC.

Clin Cancer Res. 2005 Nov 15;11(22):8172-9.

16.

Quantitative angiogenesis assays in vivo--a review.

Hasan J, Shnyder SD, Bibby M, Double JA, Bicknel R, Jayson GC.

Angiogenesis. 2004;7(1):1-16. Review.

PMID:
15302991

Supplemental Content

Loading ...
Support Center